2-(3, 4-dihydroxybenzylidene)malononitrile as a novel anti-melanogenic compound

• Published in: Oncotarget 2017-10, Vol.8 (53), p.91481-91493
• Main Authors: Lee, Bonggi, Moon, Kyoung Mi, Lim, Jong Seung, Park, Yeojin, Kim, Do Hyun, Son, Sujin, Jeong, Hyoung Oh, Kim, Dae Hyun, Lee, Eun Kyeong, Chung, Ki Wung, An, Hye Jin, Chun, Pusoon, Seo, Arnold Y, Yang, Ju-Hye, Lee, Bong-Seon, Ma, Jin Yeul, Cho, Won-Kyung, Moon, Hyung Ryong, Chung, Hae Young
• Format: Article
• Language: English
• Subjects: Research Paper
• ISSN: 1949-2553; 1949-2553
• DOI: 10.18632/oncotarget.20690

Tyrosinase is a key player in ultraviolet-induced melanogenesis. Because excessive melanin accumulation in the skin can induce hyperpigmentation, the development of tyrosinase inhibitors has attracted attention in cosmetic-related fields. However, side effects including toxicity and low selectivity have limited the use of many tyrosinase inhibitors in cosmetics. We synthesized 12 novel 2-(substituted benzylidene)malononitrile derivatives and investigated their anti-melanogenic activities. Of these 12 compounds, 2-(3, 4-dihydroxy benzylidene)malononitrile (BMN11) exhibited the strongest inhibitory activity against tyrosinase (IC = 17.05 μM). In parallel with this, BMN11 treatment notably decreased alpha-melanocyte-stimulating hormone-induced melanin accumulation in B16F10, cells without toxicity and also decreased melanin accumulation in a human skin model. As a mechanism underlying the BMN11-mediated anti-melanogenic effect, docking simulation showed that BMN11 can directly bind to tyrosinase by forming two hydrogen bonds with GLY281 and ASN260 residues, and via three hydrophobic interactions with VAL283, PHE264, and ALA286 residues in the tyrosinase binding pocket, and this likely contributes to its inhibitory effect on tyrosinase. Consistently, Lineweaver-Burk and Cornish-Bowden plots showed that BMN11 is a competitive inhibitor of tyrosinase. We concluded that BMN11 may be a novel tyrosinase inhibitor that could be used in cosmetics.